MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Investment Ideas Pro

What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

1 hour ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What is EcoCharge Solutions, and Why Does it Matter Now

1 months ago

What is Google's Gemini Embedding 2 and Why Does It Matter

1 months ago

What is Upstart's Cash Line and Why Does it Matter

2 months ago

What is PanTracer Pro and Why Does it Matter for Cancer Diagnostics

2 months ago

Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

Denali Therapeutics transitioned to a commercial-stage company after receiving FDA approval for AVLAYAH to treat Hunter syndrome. The approval validates the company's TransportVehicle platform, which ...

DNLI

Stock News•4 days ago

Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia

Larimar Therapeutics published peer-reviewed findings in Clinical and Translational Science demonstrating that skin biopsies can serve as a surrogate for measuring frataxin levels in tissues relevant ...

LRMR

Stock News•6 days ago

Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion

Eli Lilly and Profluent entered a multi-program research collaboration worth up to $2.25 billion on Tuesday. The partnership focuses on developing AI-designed enzymes for genetic medicines, marking a ...

LLY

Stock News•6 days ago

Coave Therapeutics to unveil OneAAVTM universal capsid at ASGCT 2026, paving the way for third generation gene therapy vectors

Coave Therapeutics will present data on its OneAAVTM universal capsid at the ASGCT Annual Meeting on May 11–15, 2026. The platform demonstrated up to 1000x lower liver transduction in vivo, potentiall...